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Abstract
Introduction Sex disparities exist in coronary artery
disease (CAD) in terms of risk profile, clinical management and outcome. It is unclear if differences are
also present in coronary aneurysms, a rare variant of
CAD.
Methods Patients were selected from the international Coronary Artery Aneurysm Registry (CAAR;
ClinicalTrials.gov: NCT02563626), and differences between groups were analysed according to sex. The
CAAR database is a prospective multicentre registry
of 1565 patients with coronary aneurysms (336 females). Kaplan-Meier method was used for eventfree survival analysis for death, major adverse cardiac

events (MACE: composite endpoint of death, heart
failure and acute coronary syndrome) and bleeding.
Results Female patients were older, were more often
hypertensive and less frequently smoker. They were
treated conservatively more often compared to male
patients and received significantly less frequently aspirin (92% vs 88%, p = 0.002) or dual antiplatelet therapy (DAPT) (67% vs 58%, p = 0.001) at discharge. Median DAPT duration was also shorter (3 vs 9 months,
p = 0.001). Kaplan-Meier analysis revealed no sex differences in death, MACE or bleeding during a median
follow-up duration of 37 months, although male patients did experience acute coronary syndrome (ACS)
more often during follow-up (15% vs 10%, p = 0.015).
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Conclusions These CAAR findings showed a comparable high-risk cardiovascular risk profile for both sexes.
Female patients were treated conservatively more often and received DAPT less often at discharge, with
a shorter DAPT duration. ACS was more prevalent
among male patients; however, overall clinical outcome was not different between male and female patients during follow-up.
Keywords Sex · Coronary artery aneurysms · Dual
antiplatelet therapy

the prevalence of coronary aneurysms is 0.35%. Patients with coronary aneurysms represent a very high
cardiovascular risk burden with a high proportion of
chronic kidney disease and peripheral artery disease.
Most patients receive dual antiplatelet therapy (DAPT)
or—to a lesser extent—anticoagulation and percutaneous revascularisation appear to be safe [4]. The aim
of this study is to explore any differences between
male and female patients with coronary aneurysms
in presentation, therapeutic management and clinical
outcome.

Introduction

Methods

Underlying mechanisms and clinical outcome of coronary artery disease (CAD) are different for men and
women. Studies have suggested that women exhibit
less extensive CAD and less ischaemia in stable ischaemic heart disease and more frequent plaque erosion in sudden cardiac death than men [1, 2]. Nevertheless, poor clinical outcome and suboptimal management in especially postmenopausal women is of
great concern. A rare but not uncommon variant of
CAD are coronary artery aneurysms. The prevalence
varies according to the clinical setting and geography,
ranging from 0.1 to 3.5%, being around 1.4% in postmortem studies [3, 4]. Current American and European guidelines on CAD do not mention coronary
aneurysms, while their impact on clinical outcome
is significant and their clinical management is very
challenging due to anatomical features and lack of evidence from randomised trials [5–8].
The international Coronary Artery Aneurysm Registry (CAAR) is the first study assessing contemporary therapeutic management and clinical outcome of
coronary aneurysms [9]. Recent analysis showed that

Study population

What’s new?








Coronary aneurysms are a manifestation of advanced stages of atherosclerosis in both men and
women.
In this study, female patients were treated
conservatively more often and less frequently
received aspirin or dual antiplatelet therapy
(DAPT) at discharge. In addition, DAPT duration
in female patients was also shorter.
Male patients experienced acute coronary syndrome (ACS) more frequently during long-term
follow-up; however, all-cause death and major
adverse cardiac events (composite of all-cause
death, ACS and heart failure) did not differ between the sexes.
Despite female patients less frequently receiving DAPT and with a shorter duration, bleeding
events during follow-up were similar between
the sexes.

Insights from the international coronary artery aneurysm registry

The rationale and design of the CAAR (ClinicalTrials.gov registration nr. NCT02563626) have been described previously [9]. In short, the CAAR is an international multicentre ambispective registry that recruited patients from 32 hospitals across nine countries (Canada, Cuba, Czech Republic, Germany, Italy,
the Netherlands, Spain, United States and Uruguay).
Patients (age ≥ 18 years) were included in the registry when they met the following diagnostic criterion:
a focal coronary dilation 1.5 times the diameter of
a normal adjacent segment or largest coronary vessel.
A giant aneurysm was defined as a 4-fold focal dilation compared with the reference vessel diameter or
a focal diameter size > 8 mm. Excluded was coronary
ectasias, defined as a diffuse (more than one-third of
vessel length) 1.5-fold dilation of the coronary artery.
Coronary aneurysm shapes were described as saccular
when bulging of the vessel wall occurred on one side
of the vessel and as fusiform in case of circumferential
bulging on all sides.
Aortopathy was defined as a medical history of one
or more of the following conditions: aneurysm, dissection or coarctation. Connective tissue disorders
included scleroderma, Marfan syndrome and EhlersDanlos syndrome. Angiographic data were reviewed
by two independent interventional cardiologists of the
including centre. If no agreement was reached in
the assessment of these data (e.g. eligibility, type of
aneurysm or size), angiographic images were submitted to the core centre (Hospital Clínico San Carlos).
Data collection was in accordance with regulations
set forth by institutional review boards and complied
with the Declaration of Helsinki.

Clinical outcome and follow-up
Clinical characteristics and complications during the
index hospitalisation (e.g. cardiogenic shock, bleeding and death) were recorded. Follow-up data and
events were prospectively obtained based on outpatient medical visits and records or telephone interviews. After discharge, death from any cause,
hospitalisation due to unstable angina, (re)infarction,
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Table 1

Baseline characteristics

Variable
Age, years

Male (n = 1229)
65 ± 12

Female (n = 336)
68 ± 14

P-value
< 0.001

Diabetes mellitus

316 (26)

87 (26)

Hypertension

859 (70)

272 (81)

Ns
< 0.001

Dyslipidaemia (%)

732 (60)

197 (59)

Ns

Smoking habit (%)

575 (47)

70 (21)

< 0.001

Family history of CAD

126 (10)

34 (10)

Ns

Previous CAD

495 (40)

90 (27)

< 0.001

Peripheral vascular disease

143 (12)

32 (10)

Ns

93 (8)

36 (11)

Ns

Renal insufficiency (CrCl < 30 ml/min)
Kawasaki disease
Connective tissue disease
Aortic aneurysms or pathology

2

2

25 (2)

9 (3)

126 (10)

11 (3)

132 (11)

49 (15)

33 (3)

10 (3)

Clinical presentation
Chest pain
Dyspnoea/heart failure

200 (16)

44 (13)

NSTEMI

505 (41)

143 (43)

STEMI

269 (22)

51 (15)

60 (5)

35 (10)

1085 (88)

276 (82)

Severe stenosisa

Ns
< 0.001
Ns

Stable Angina

Valvular study

Ns

Number of diseased vessels with stenosis

0.001
Ns

1

348 (28)

2

335 (27)

89 (26)
64 (19)

3

402 (33)

123 (37)

Fusiform

546 (44)

139 (41)

Saccular

649 (53)

186 (55)

Aneurysm type

Ns

Mixed

34 (3)

9 (3)

Giant aneurysms

70 (6)

12 (4)

Ns

Size, mm (median (interquartile range))b

5.3 (2.5)

5.0 (1.8)

Ns

Number of aneurysms per patient (median (range))

1 (6)

1 (3)

Ns

LM

66 (5)

18 (5)

LAD

587 (48)

175 (52)

RCx

354 (29)

87 (26)

RCA

408 (33)

90 (27)

54 ± 13

56 ± 13

Coronary territoryc

LVEF, %

Ns

0.027

Data are mean ± standard deviation, n (%) or as otherwise stated
CAD coronary artery disease, CrCl creatinine clearance, (N)STEMI (non-)ST-segment elevation myocardial infarction, LM left main, LAD left anterior descending
coronary artery, RCx ramus circumflexus, RCA right coronary artery, LVEF left ventricular ejection fraction, ns not significant
a
Severe stenosis was defined as stenosis > 70% in coronaries and > 50% in left main artery
b
In case of multiple aneurysms in one patient, largest size was included in analysis
c
More than one aneurysm could be present in same vessel and/or in different coronary territories

heart failure, bleeding, stroke, embolic events and
any reason for coronary angiography were recorded.
A combined clinical endpoint of major adverse cardiac events (MACE) was defined as the combination
of all-cause death, hospitalisation for heart failure
and acute coronary syndrome (ACS). The use of antiplatelet and anticoagulation therapy and the choice
for revascularisation (if any) were studied during the
index hospitalisation and follow-up.

Statistical analysis
Continuous data are presented as mean with standard
deviation (SD) or median with interquartile range
(IQR) and categorical data as numbers (percentages
of total). Differences between male and female patients were analysed using the Student’s t-test for
continuous variables and the χ2 test or Fisher’s exact
test for categorical variables. Kaplan-Meier estimates
with log-rank test were used for survival analysis and
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Table 2

Treatment strategy at discharge

Treatment strategy
Conservative (medical) therapy

Male (n = 1229)
362 (29)

Female (n = 336)
124 (37)

P-value
0.01

Revascularised segment
Aneurysmatic

436 (35)

125 (37)

Ns

Nonaneurysmatic

727 (59)

178 (53)

0.042

40 (3)

5 (1)

PCI – BMS

202 (16)

57 (17)

PCI – DES

406 (33)

87 (26)

Revascularisation strategy
Balloon angioplasty only

Drug-eluting balloon

Ns

6

1

CABG

191 (16)

59 (18)

Aspirin

1133 (92)

294 (88)

DAPT

827 (67)

195 (58)

DAPT duration, months

9 (0–12)

3 (0–12)

0.002
0.001
0.001

Anticoagulation

163 (13)

56 (17)

Ns

Triple therapy

67 (5)

19 (6)

Ns

Data are n (%) or median (interquartile range)
PCI percutaneous coronary intervention, BMS bare metal stent, DES drug-eluting stent, CABG coronary artery bypass grafting, DAPT dual antiplatelet therapy,
ns not significant

group comparisons, respectively. The level of statistical significance was set at two-tailed p ≤ 0.05 (SPSS
v24, IBM, USA).

Results
A total of 1565 patients were included in the CAAR for
final analysis, as described previously [4]. Compared
with the male patients, the female patients (n = 336;
21% of total cohort) were older at presentation (65 ± 12
vs 68 ± 14 years; p < 0.001) and more often hypertensive (70% vs 81%; p < 0.001) (Tab. 1). They less frequently had a smoking habit (47% vs 21%; p < 0.001),
less frequently had previous coronary artery disease
(40% vs 27%; p < 0.001), less frequently had a history of aortic aneurysms or related pathology (10% vs
3%; p < 0.001) and less frequently had severe coronary
stenosis (88% vs 82%; p = 0.001).
Diabetes mellitus, family history of CAD and dyslipidaemia were equally distributed between male and
female patients. No differences were found in the
clinical presentation, the extent of CAD or type of
aneurysm. The size and number of aneurysms per
patient did not differ between sexes, nor did the coronary territories supplied by aneurysms (Tab. 1).
Female patients received conservative treatment
more frequently than the male patients (37% vs 29%,
p = 0.01) (Tab. 2). In invasively treated patients, no
differences were found in revascularised aneurysmatic segments. However, nonaneurysmatic lesions
were treated more frequently in male patients (59% vs
53%; p = 0.042). The type of revascularisation strategy
was not different between male and female patients.
No sex differences were found in the choice for bare
metal stents, drug-eluting stents or coronary artery
bypass grafting (CABG). Female patients received
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significantly less frequently aspirin or DAPT at discharge. In addition, median DAPT duration was also
significantly shorter compared with male patients (3
vs 9 months, p = 0.001). It is unknown to what extent the shorter duration was related to physician’s
prescription behaviour or patient compliance. The
percentage of patients on anticoagulation was higher
in the female group, but this difference was not statistically significant (Tab. 2). Clopidogrel was the most
frequently chosen P2Y12 inhibitor in both female and
male patients (94% vs 93%) (data not shown).
Kaplan-Meier survival analysis revealed no statistically significant differences in the occurrence of death,
MACE or bleeding during a median follow-up duration of 37 months (IQR 15–72) (Fig. 1). Total number of deaths was 240 (18% of females, 15% of males)
(Tab. 3). MACE occurred in 485 cases (29% of females,
32% of males) and bleeding in 89 patients (4% of females, 6% of males). During follow-up, male patients
were diagnosed more frequently with ACS.

Discussion
The current analysis showed that coronary aneurysms
exist in the context of severe and extensive CAD and
that invasive management was chosen equally often
in both sexes. Surprisingly, female patients received
less frequently aspirin or DAPT—and the duration of
DAPT was shorter—without any differences in death,
MACE or bleeding during follow-up.
Sex differences exist, and they remain challenging
for ischaemic heart disease in terms of clinical presentation and management, as well as outcome. In
coronary aneurysms, the challenge is even greater
in the absence of guideline-supported recommendations and prospective clinical studies. In that context,
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Fig. 1 Kaplan-Meier curves for event-free survival from
a death, b major adverse cardiac events (MACE) and c bleeding

the CAAR findings provide a unique insight into both
clinical characteristics and therapeutic management
along with long-term outcome data representative for
a significant part of the world.
In the absence of other causes than atherosclerosis,
coronary aneurysms are considered a variant of CAD.
This is supported by the high prevalence of multiple
risk factors for cardiovascular disease (Tab. 1). The
subgroup analysis of the ISCHEMIA trial showed that
female patients had less extensive CAD with less severe ischaemia [1]. The CAAR findings suggest that
coronary aneurysms are at a different level of the CAD
spectrum. The slightly higher age at presentation together with the fact that the number of vessels with
severe stenosis is also high may suggest that coronary
aneurysms are indeed an advanced stage of CAD.
There are many analyses showing that disparities
between the sexes exist in clinical presentation and
in management of ischaemic heart disease. Even in
the setting of ACS, women are less likely to receive
guideline-recommended therapeutics such as aspirin
and statins, which may partly explain the difference
in clinical outcome [10, 11].
In our study, a significantly higher percentage of
female patients were treated conservatively, probably related to the lower number of severe stenotic
lesions in women. Approximately 45–50% of the patients did undergo percutaneous coronary intervention and about 15% underwent CABG. Both male and
female patients received any type of revascularisation
to a similar degree, and both groups received mostly
clopidogrel when a P2Y12 receptor inhibitor was prescribed. Given that equal proportions of male and
female patients received invasive therapy, the differences in the use of antiplatelet therapy are surprising
but are largely in line with the results of previous reports [10, 11]. Besides less frequent prescription of
aspirin or DAPT in female patients at discharge, the
DAPT duration was significantly shorter in female patients.
Several recent analyses from contemporary trials and registries such as PARIS, CARDIOBASE and
GLOBAL LEADERS have clearly demonstrated that
women have a higher risk of drug-related bleedings
and that this is an important reason for DAPT cessation [12–14]. Although with the CAAR database, it
was not possible to explore the arguments behind the
differences in medical treatment between male and
female patients, one could argue that the higher risk
of bleeding complications in women may have played
an important role for physicians to prescribe DAPT
less often and with a shorter duration in women in
the absence of clear guideline recommendations for
coronary artery aneurysms. In patients with ACS, for
whom guidelines clearly recommend 12 months of
DAPT, the duration of DAPT did not differ between
the sexes: the median duration in both sexes was
12 months. This was also the case for patients who
received a drug-eluting stent: 92% of the female and
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Table 3

Outcome during follow-up

Outcome
Death
Cardiovascular

Male (n = 1229)
181 (15)

Female (n = 336)
59 (18)

P-value
Ns

57 (5)

29 (9)

0.01

MACE

387 (31)

98 (29)

Ns

ACS

190 (15)

35 (10)

0.015

HF

97 (8)

34 (10)

Ns

Bleeding

75 (6)

14 (4)

Ns

Stroke

25 (2)

Embolic events

9 (0.7)

6 (2)

Ns

3 (0.9)

Ns

Data are n (%)
MACE major adverse cardiac events—composite endpoint of death, acute coronary syndrome (ACS) and heart failure (HF), ns not significant

93% of the male patients who received a drug-eluting
stent were given DAPT (data not shown). Again, the
median DAPT duration in both sexes was 12 months.
Nevertheless, the adherence to guideline recommendations for ACS was only observed for the duration of
DAPT.
Additional analysis in the same ACS subpopulation
revealed that the number of patients who were prescribed aspirin and DAPT at discharge were significantly lower in female than in male patients (89%
vs 96%, p < 0.001 and 71% vs 81%, p = 0.032, respectively). The notion that the higher bleeding risk in
women made physicians reluctant to prescribe less
and shorter-lasting DAPT was also supported by the
observation that bleeding events occurred to the same
degree in male and female patients. Either reduced
prescription of DAPT at discharge or premature cessation of DAPT during follow-up may have been related
to unrecorded events of bleeding or other adverse
(side) effects in female patients. Altogether, less and
shorter-lasting DAPT may have reduced the bleeding
rate in female patients to a level that is similar to that
in male patients. In addition, the higher rate of female patients treated conservatively could also have
resulted in less frequent DAPT and may be related to
the lower number of severe stenotic lesions.
The issue of sex disparities is a complex interplay of
psychological and biological factors, and of patients’
and healthcare providers’ perceptions on cardiovascular disease in women [15]. An important factor
is the perception—of both patients and healthcare
providers—that women have a low risk of cardiovascular disease, causing delays in medical contact and
differences in clinical management. While the coronary anatomy was known in our study (all patients
had to undergo invasive angiography) and delays in
medical contact were not recorded, it might have
been the perception of physicians that women with
coronary aneurysms ought to be treated differently
than men. It is possible that the relative rareness of
coronary aneurysms caused the differences in (D)APT
and its duration since there are no clear guideline
recommendations or clinical trial results to guide our
decision-making process. However, even in ‘clear-cut’
clinical presentations such as ST-segment elevation
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myocardial infarction, contemporary studies have
demonstrated that women around the globe still experience differences in diagnosis, (invasive) treatment
and post-myocardial infarction rehabilitation [16–18].
This demonstrates once again the importance of continuing education and increasing awareness among
patients and healthcare providers.
Despite the differences in especially DAPT, there
were no statistical differences in death and MACE
observed between the sexes. Subgroup analysis did
reveal a significant difference in the number of cardiovascular deaths (more frequently diagnosed in
women). The difference in confirmed cardiovascular
deaths could be related to chance or factors that are
associated with observational studies, such as the
impossibility to confirm the cause of death in all included patients. The higher incidence of ACS in male
patients during follow-up—despite more frequent
DAPT prescription—could be explained by the more
than twice as high number of male smokers, more
frequent previous CAD and more significant coronary
stenosis.

Study limitations
The CAAR is limited by its observational character, thereby lacking information about the rationale
for shortened or altered antiplatelet regimes or the
observed differences during follow-up. Despite the
prospective collection of follow-up data, a systematic approach could have assured more reliable and
complete data for example for drug discontinuation.
A second limitation is the potential for inclusion bias
because only patients who underwent invasive coronary angiography were included in the registry. This
criterion skewed the population towards ACS and
patients with high-risk features, while studies have
clearly demonstrated that women are less likely to
undergo invasive coronary angiography [10, 19]. An
unknown number of patients were not included who
could have been identified with other noninvasive
modalities (e.g. coronary computed tomography).
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Conclusion
In the light of the current analysis, both male and female patients with coronary aneurysms have a very
high-risk atherosclerotic profile, a similar extent of
CAD and similar clinical outcome despite differences
in antiplatelet and invasive treatment strategies. The
question remains whether equality in treatment strategy would have changed the clinical outcome in female patients with coronary aneurysms. The data also
suggest that we need to increase awareness regarding women’s risk of cardiovascular disease and disparities in clinical management. Future studies are
necessary to clarify the impact of equal antiplatelet/
antithrombotic strategy and invasive management in
women with coronary aneurysms in terms of net clinical outcome (bleeding vs ischaemic risk).
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